**Supplementary Table 3** PRo-HCM: Major differences between low- and high-volume centers.

a <15 patients; b >100 patients.

|  |  |  |  |
| --- | --- | --- | --- |
|  | Low-volume centersa | High-volume centersb | p |
| Number of centers | 16 | 3 |  |
| Number of patients | 104 | 415 |  |
| Age at first consultation | 53 years | 49 years | <0.05 |
| Familial HCM | 18 | (21%) | 208  | (51%) | <0.001 |
| Genetic testing | 22 | (21%) | 206  | (50%) | <0.001 |
| Family screening (genetic cascade) | 8 | (8%) | 208  | (50%) | <0.001 |
| Exclusion of phenocopies | 12 | (12%) | 216  | (52%) | <0.001 |
| 24-hour ECG monitoring | 79 | (76%) | 367  | (88%) | <0.01 |
| Exercise echo | 5 | (5%) | 64  | (15%) | <0.05 |
| CCT/invasive angiography |  |  |  |  |  |
| Disopyramide | 0 | (0%) | 17  | (4%) | <0.05 |
| Amiodarone | 6 | (6%) | 74  | (18%) | <0.005 |
| Diuretics | 10 | (10%) | 90  | (22%) | <0.005 |
| ACEIs | 28 | (27%) | 56  | (14%) | <0.001 |
| ARBs | 16 | (15%) | 35  | (8%) | <0.05 |

ACEIs: angiotensin-converting enzyme inhibitors; ARBs: angiotensin receptor blockers; CCT: cardiac computed tomography; ECG: electrocardiogram; HCM: hypertrophic cardiomyopathy.